Advertisement

Topics

Latest "IGI Incorporated" News Stories

13:43 EST 23rd February 2019 | BioPortfolio

Here are the most relevant search results for "IGI Incorporated" found in our extensive news archives from over 250 global news sources.

More Information about IGI Incorporated on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about IGI Incorporated for you to read. Along with our medical data and news we also list IGI Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of IGI Incorporated Companies for you to search.

Showing "Incorporated" News Articles 1–25 of 28

Thursday 21st February 2019

Teleflex Reports Fourth Quarter and Full Year 2018 Results; Provides 2019 Guidance

Fourth Quarter 2018 Revenues of $641.6 million, up 7.8% Versus Prior Year Period; up 9.4% on a Constant Currency Basis Fourth Quarter 2018 GAAP Diluted EPS from Continuing Operations of $1.87, up 303.3% Versus the Prior Year Period Fourth Quarter 2018 Adjusted Diluted EPS from Continuing Operations of $2.77, up 13.5% Versus Prior Year Per...


Thursday 7th February 2019

Ligand Reports Fourth Quarter and Full Year 2018 Financial Results

Conference Call Begins at 4:30 p.m. Eastern Time TodayAnalyst day to be held on Tuesday March 12 at 10:00 a.m. Eastern Time in New York City Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2018, and provided an operating forecast and program updates. Ligand ...

Wednesday 23rd January 2019

A new tool from JEOL for structural analysis of pharmaceutical mixtures

17 January 2019, PEABODY: JEOL USA has developed new methodology using the company’s ROYAL HFX Probe to offer a powerful and practical alternative for the elucidation of crucial structural information. It has particular merit in the analysis of complex pharmaceutical mixtures that contain a drug substance plus its various metabolites. It’s a familiar challenge for pharmaceutical...


Friday 11th January 2019

Redx Pharma Plc REDX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

Summary   Redx Pharma Plc Redx Pharma, formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. Redx Pharma uses its proven drug discovery expertise to generate development candidates that it will take into the clinic and then partner. The company’s product development strategy has three interrelated componen...

Wednesday 12th December 2018

Sparton Corporation to Be Acquired by Cerberus

Transaction Provides a Significant Premium to Shareholders and a Strong Partner to Support Future Growth Sparton Corporation (“Sparton” or the “Company”) (NYSE:SPA) today announced that it has entered into a definitive agreement to be acquired by an affiliate of Cerberus Capital Management, L.P. (“Cerberus”), a global leader in alternative ...

Sunday 9th December 2018

CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR’s Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson’s Disease 

Itanapraced blocks LRRK2 expression and LRRK2-mediated neurotoxicity Itanapraced ready to advance to Phase 2 in Parkinson’s disease patients with and without genetic mutation NEW YORK and SINGAPORE, Dec. 10, 2018 (GLOBE NEWSWIRE) -- CERESPIR INCORPORATED a pharmaceutical company engaged in the discovery and development of disease-modifying therapeutics for the treatment of neurodegenerative...

Friday 30th November 2018

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx

Akebia Urges Shareholders to Vote “FOR” the Merger-Related Shareholder Proposals Today Akebia Therapeutics, Inc. (Nasdaq:AKBA) (“Akebia” or the “Company”) today announced that leading independent proxy advisory firm, Glass Lewis & Co. (“Glass Lewis”), joins Institutional Shareholder Services (“ISS”) in recommending that Akebia s...

Thursday 29th November 2018

Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx

Akebia Urges Shareholders to Vote “FOR” the Merger-Related Shareholder Proposals Today Akebia Therapeutics, Inc. (Nasdaq:AKBA) (“Akebia” or the “Company”) today announced that leading independent proxy advisory firm, Institutional Shareholder Services (“ISS”), recommends that Akebia shareholders vote “FOR” the shareholder proposals ...

Probiodrug AG Reports Third Quarter 2018 Business Update

Probiodrug / Probiodrug AG Reports Third Quarter 2018 Business Update . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Probiodrug AG Reports Third Quarter 2018 Business Update HALLE (SAALE), Germany, 29 November 2018 - Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company d...

Tuesday 13th November 2018

Akebia Therapeutics Sends Letter to Shareholders

Recommends Shareholders Vote “FOR” the Proposals Relating to the Merger Akebia Therapeutics, Inc. (Nasdaq: AKBA) mailed a letter to Akebia shareholders in connection with the special meeting of Akebia shareholders (the “Special Meeting”) that has been called to approve shareholder proposals relating to the previously announced proposed m...

Sunday 11th November 2018

BioDuro LLC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

Summary 2015 - BioDuro is reacquired from PPD. BioDuro and Formex merge to enable service offerings that span from API synthesis to formulation development and cGMP manufacture of drug product. BioDuro LLC BioDuro, a subsidiary of Pharmaceutical Product Development LLC is a discoverer and developer of small molecule and biologics. The institute offers discovery, development and manufacturing...

Thursday 8th November 2018

Ligand Reports Third Quarter 2018 Financial Results

Raises 2018 Financial Guidance Conference Call Begins at 9:00 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates. Ligand management will host a conference call today b...

Wednesday 7th November 2018

Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products Heidelberg, Germany and Cambridge, UK, 07 November 2018 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced a supply and license agreement with United States based Life Sciences company, Quanterix Corporation. The agreement provi...

Tuesday 6th November 2018

Mannatech Reports Third Quarter 2018 Financial Results

Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2018. Third Quarter Results Third quarter net

Thursday 1st November 2018

Teleflex Reports Third Quarter 2018 Results

Third Quarter Revenues of $609.7 million, up 14.0% Versus Prior Year Period; up 15.0% on Constant Currency Basis Third Quarter GAAP Diluted EPS of $1.21, down 28.8% Over the Prior Year Period Third Quarter Adjusted Diluted EPS of $2.52, up 18.9% Versus Prior Year Period Lowered 2018 Guidance Range for GAAP Revenue Growth f...

Tuesday 16th October 2018

Arcis Biotechnology and Teleflex sign license agreement

Agreement gives Teleflex access to Arcis’ nucleic acid sample preparation technology Daresbury, UK, 16 October 2018: Arcis Biotechnology (“Arcis”), the nucleic acid sample preparation solution provider, today announced it has signed a technology access agreement with Teleflex Incorporated, a New York Stock Exchange listed company (NYSE: TFX). Teleflex will harness Arcis&rs...

Thursday 4th October 2018

Teleflex Acquires Essential Medical

Acquisition expands presence in structural heart and endovascular aneurysm repair markets by adding unique large bore closure system Teleflex Incorporated (NYSE: TFX) today announced that it has acquired Essential Medical, Inc. Based in Exton, PA, Essential Medical is a privately-held medical device company that has developed and commercialized the CE ...

Wednesday 3rd October 2018

Redx Pharma Plc REDX Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24072018] Prices from USD $250

Summary   Redx is a UK biotechnology company and drug development company focused on cancer and fibrosis. Its shares are traded on AIM (AIM:REDX). Redx’s vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.   Redx Pharma Plc REDX Pharmaceuticals Healt...

Saturday 29th September 2018

Global Fire Protection Materials Market Status and Outlook 20182025 [Report Updated: 19082018] Prices from USD $4000

Report SnapshotKey Content of Chapters Including and can be customized, report is a semifinished version, and it takes 4872 hours to upgradePart 1:Terminology Definition, Industry Chain,Industry Dynamics Regulations and Global Market OverviewPart 2:Upstream Raw Materials / Components Manufacturing Procurement Methods Channels and Cost , Major Regional Production Overview and Trade FlowPart 3:Pr...

Tuesday 11th September 2018

Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis

Novartis International AG / Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Global headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office  The listed ...

Friday 7th September 2018

University of Houston chooses JEOL for its growing NMR needs

7th September 2018: The University of Houston has added two new JEOL NMR systems to its existing suite as demand for NMR spectroscopy among students and researchers grows. The University of Houston’s chemistry department now has four NMR systems and the pharmacy department has one – all from JEOL Inc. Users come from a range of disciplines, with biology, physics and engineering ...

Tuesday 4th September 2018

NANOBIOTIX half year results for the six months ended June 30, 2018

  Nanobiotix half year results for the six months ended June 30, 2018 Major milestones achieved with the success of Soft Tissue Sarcoma phase III clinical trial with first-in-class NBTXR3 product Overall expenses according to plan Post cloture event: financial partnership

Tuesday 28th August 2018

Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the appointment of Cynthia Smith to its Board of Directors. “Cynthia is an accomplished leader with an impressive background in the...

Thursday 23rd August 2018

Global Sorbitol Market Segmented by Form, Function, Application and Geography 2018 2023 [Report Updated: 08022018] Prices from USD $4250

Merck one of the leading sorbitol manufactures developed directly compressible sorbitol Parteck SI . The unique particle structure of Parteck SI gives it distinctive physical properties, making it the perfect excipient for combining many ingredients into one elegant and robust tablet formulation. The market was is expected to reach USD 1.28 billion by 2023, registering a CAGR of 5.5%, during 20182...

Friday 17th August 2018

Global Next Generation Sequencing Informatics Market Segmented by Services Type, Applications and End Users Growth, Trends and Forecasts 2018 2023 [Report Updated: 01032018] Prices from USD $4250

The global next generation sequencing informatics market is expected to register a CAGR of about 22.0% during 20182023 the forecast period. North America is dominating the market, due to the growing demand for NGS informatics product services in the region.Growing Demand for NGS Service and Rising Investment by Key PlayersThe next generation sequencing NGS informatics services have gained popula...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks